Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 2/20 | 0.48 |
| ▸ | CTSA | P10619 | 14/20 | 0.46 |
| ▸ | PDE2A | O00408 | 1/20 | 0.44 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.43 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGAV | P06756 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15636858 | 0.90 | CTSA (0.53) | MMP12CTSAPDE2AITGB3ITGAV | |
| SCHEMBL15635913 | 0.89 | EGLN2 (0.50) | CTSAITGB1ITGA4 | |
| SCHEMBL15636782 | 0.88 | CTSA (0.59) | CTSA | |
| SCHEMBL15637590 | 0.88 | CTSA (0.59) | CTSACYP3A4MME | |
| SCHEMBL15636162 | 0.87 | CTSA (0.57) | CTSACYP3A4MME | |
| SCHEMBL15635751 | 0.87 | CTSA (0.56) | CTSA | |
| SCHEMBL15636345 | 0.86 | CTSA (0.57) | MMP12CTSA | |
| SCHEMBL15635374 | 0.86 | CTSA (0.56) | CTSAPDE2A | |
| SCHEMBL15636851 | 0.85 | CTSA (0.50) | CTSACYP3A4MME | |
| SCHEMBL16223856 | 0.85 | CTSA (0.57) | CTSA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014053533-A1 | USE OF SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AS PHARMACEUTICALS FOR PREVENTION/TREATMENT OF ATRIAL FIBRILLATION | SANOFI (FR) | 2014-04-10 | — | — | WO | disclosed |